Tiotropium + Olodaterol (Torracto [TM]) in COPD

• Research type

  Research Study

• Full title

  A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg, 5/5 µg) delivered by the Respimat® Inhaler, on exercise endurance time during constant work rate cycle ergometry in patients with Chronic Obstructive Pulmonary Disease (COPD) [TorractoTM]

• IRAS ID

  93268

• Contact name

  D Singh

• Sponsor organisation

  Boehringer Ingelheim

• Eudract number

  2011-004253-11

• Research summary

  The purpose of this study is to determine the effect of tiotropium olodaterol fixed dose combination for inhalation on exercise endurance, breathing discomfort and lung volumes in patients with Chronic Obstructive Pulmoanry Disease (COPD). Since tiotropium and olodaterol work in different ways, combining the two medicines can open up the air passages in the lungs more than each medicine alone. Patients will be asked to participate in this trial to evaluate the investigational combination of tiotropium olodaterol inhaled together in the same Respimat© device. The Respimat© is different from inhalers that are currently available.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  12/NW/0082

• Date of REC Opinion

  29 Feb 2012

• REC opinion

  Further Information Favourable Opinion